# Institut Georges Lopez-2M as a Novel Lung Preservation Solution Attenuates Ischemia-Reperfusion Injury in a Rat Ex Vivo Lung Perfusion Model

**Authors:** Annalisa Barbarossa, Jan Van Slambrouck, Cara Trivett, Phéline Kortleven, Cedric Vanluyten, Alberto Martin Medina, Xin Jin, Nicole Jannis, Balin Özsoy, Sandra Claes, Dominique Schols, Tine Wylin, Karen Moermans, Steve Stegen, Arnau Panisello Rosello, Ilhan Inci, Paul De Leyn, Bart Vanaudenaerde, Jacques Pirenne, Elizabeth A. V. Jones, Laurens J. Ceulemans

PMC · DOI: 10.3389/ti.2026.15993 · Transplant International · 2026-02-19

## TL;DR

A new lung preservation solution, IGL-2M, reduces lung injury during cold storage in a rat model, showing better protection than existing solutions.

## Contribution

IGL-2M is a novel preservation solution that effectively reduces ischemia-reperfusion injury in lungs.

## Key findings

- IGL-2M reduced edema formation and improved lung compliance compared to OCS.
- IGL-2M showed lower inflammatory markers in perfusate and bronchoalveolar lavage.
- IGL-2M was not inferior to Perfadex Plus and reduced TNF-α expression.

## Abstract

Institut
Georges Lopez-2M (IGL-2M), a novel preservation solution containing polyethylene glycol (PEG 35kD, 5 g/L), preserves mitochondrial integrity and redox balance in liver grafts. This study assesses IGL-2M’s effect on lung preservation during prolonged cold ischemia. Rat’s heart-lung blocks were procured and subjected to 18 h cold ischemia (4 °C). Lungs were flushed and preserved using one of these preservation solutions: OCS, Perfadex Plus, IGL-2M (n = 6/group). Following ischemia, lungs underwent up to 7 h normothermic ex vivo lung perfusion. Edema was quantified by weight gain. Lung physiological parameters were recorded. Perfusate, bronchoalveolar lavage (BAL), and tissue samples were collected. All lungs in IGL-2M group completed 7 h EVLP protocol. Compared to OCS, IGL-2M reduced edema formation (p < 0.01), preserved superior compliance (p < 0.01), and maintained lower pulmonary vascular resistance (p < 0.01). IGL-2M showed lower perfusate concentrations of IL-1β (p < 0.05), IL-6 (p < 0.05), and TNF-α (p = 0.08). In BAL, IGL-2M reduced IL-1β (p < 0.01), IL-6 (p < 0.05), TNF-α (p < 0.01), and CXCL1 (p < 0.01). IGL-2M showed lower release of Syndecan-1 (p < 0.05). Compared to Perfadex Plus, IGL-2M was not inferior, with reduced expression of TNF-α in the perfusate (p < 0.05). IGL-2M effectively prevents edema development like Perfadex Plus. IGL-2M results in decreased inflammation and a stronger endothelial lining, making it a promising solution for lung preservation.

Scientific summary graphic comparing OCS, Perfadex Plus, and IGL-2M preservation solutions in a rat lung perfusion model following cold ischemia, featuring schematic, photo, and two data plots showing IGL-2M reduces edema and strengthens vascular integrity relative to controls.

## Linked entities

- **Proteins:** IL1B (interleukin 1 beta), IL6 (interleukin 6), TNF (tumor necrosis factor), CXCL1 (C-X-C motif chemokine ligand 1), sdc1.L (syndecan 1 L homeolog)
- **Chemicals:** polyethylene glycol (PubChem CID 9033)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Il10 (interleukin 10) [NCBI Gene 25325] {aka IL10X, If2a}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Sdc1 (syndecan 1) [NCBI Gene 25216] {aka HSPG, SYNDECA, Synd1, Syndecan}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Actg2 (actin gamma 2, smooth muscle) [NCBI Gene 25365] {aka ACTGE, SMGA}, Rela (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 309165] {aka NFkB, nos2}, Cdh5 (cadherin 5) [NCBI Gene 307618], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Habp2 (hyaluronan binding protein 2) [NCBI Gene 292126] {aka Fsap, Habp, Phbp}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 81503] {aka CINC-1, Gro1}, Tumor necrosis factor [NCBI Gene 103694380], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}
- **Diseases:** Weight gain (MESH:D015430), EVLP failure (MESH:D012131), heart-lung block (MESH:D006327), dysfunction (MESH:D006331), Ischemia (MESH:D007511), tissue injury (MESH:D017695), mitral valve (MESH:D008944), hypoxemia (MESH:D000860), Inflammation (MESH:D007249), IRI (MESH:D015427), pulmonary flush (MESH:D005483), microvascular injury (MESH:D017566), PK (MESH:C564858), ischemic (MESH:D002545), vascular leak (MESH:D019559), endothelial injury (MESH:D057772), PGD (MESH:D055031), pulmonary edema (MESH:D011654), EVLP (MESH:C536830), Edema (MESH:D004487)
- **Chemicals:** water (MESH:D014867), ATP (MESH:D000255), TNT (MESH:D014303), CO2 (MESH:D002245), isoflurane (MESH:D007530), Perfadex (MESH:C070005), tungsten carbide (MESH:C002802), Tween -20 (MESH:D011136), biotin (MESH:D001710), heparin (MESH:D006493), HCl (MESH:D006851), DAPI (MESH:C007293), formaldehyde (MESH:D005557), ethanol (MESH:D000431), Calcium (MESH:D002118), Hyaluronan (MESH:D006820), ROS (MESH:D017382), FITC-dextran (MESH:C015219), pO2 (MESH:C093415), Paraffin (MESH:D010232), 385911-50UG (-), NaCl (MESH:D012965), Dextran (MESH:D003911), potassium (MESH:D011188), O2 (MESH:D010100), THAM (MESH:D014325), xylene (MESH:D014992), lactate (MESH:D019344), N2 (MESH:D009584), PEG (MESH:D011092)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** IGL-2 — Homo sapiens (Human), Transformed cell line (CVCL_VM44), -2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960282/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960282/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960282/full.md

---
Source: https://tomesphere.com/paper/PMC12960282